IASLC WCLC 2022: Editor’s highlights

With the IASLC World Conference on Lung Cancer (Vienna, Austria, 6–9 August 2022) wrapping up, we have summarized the key news stories and talks to emerge from the conference. Continue reading to discover results from the NADIM II trial, DOLPHIN study as well as the IMPower010 trial. News highlights Intertumoral heterogeneity of METex14 skipping positive NSCLCs unearthed MET exon 14 skipping is a rare driver of NSCLC, however despite the fact that it can be successfully targeted by MET-specific TKI’s, recent clinical trials have suggested there are differences in the biology of NSCLC tumors driven by METex14 skipping, as suprisingly almost...